Robot-assisted radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy (iROC): protocol for a randomised controlled trial with internal feasibility study by Catto, J.W.F. et al.
This is a repository copy of Robot-assisted radical cystectomy with intracorporeal urinary 
diversion versus open radical cystectomy (iROC): protocol for a randomised controlled trial
with internal feasibility study.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/134864/
Version: Published Version
Article:
Catto, J.W.F., Khetrapal, P., Ambler, G. et al. (12 more authors) (2018) Robot-assisted 
radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy 
(iROC): protocol for a randomised controlled trial with internal feasibility study. BMJ Open, 
8 (8). e020500. 
https://doi.org/10.1136/bmjopen-2017-020500
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) 
licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new 
works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative 
works on the same terms. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
1Catto JWF, et al. BMJ Open 2018;8:e020500. doi:10.1136/bmjopen-2017-020500
Open access 
Robot-assisted radical cystectomy with 
intracorporeal urinary diversion versus 
open radical cystectomy (iROC): 
protocol for a randomised controlled 
trial with internal feasibility study
James W F Catto,1,2 Pramit Khetrapal,2 Gareth Ambler,3 Rachael Sarpong,4 
Muhammad Shamim Khan,5 Melanie Tan,4 Andrew Feber,2 Simon Dixon,6 
Louise Goodwin,1 Norman R Williams,4 John McGrath,7 Edward Rowe,8 
Anthony Koupparis,8 Chris Brew-Graves,4 John D Kelly2
To cite: Catto JWF, Khetrapal P, 
Ambler G, et al.  Robot-
assisted radical cystectomy 
with intracorporeal urinary 
diversion versus open 
radical cystectomy (iROC): 
protocol for a randomised 
controlled trial with internal 
feasibility study. BMJ Open 
2018;8:e020500. doi:10.1136/
bmjopen-2017-020500
 Ź Prepublication history for 
this paper is available online. 
To view these iles, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2017- 
020500).
Received 9 November 2017
Revised 17 May 2018
Accepted 7 June 2018
For numbered afiliations see 
end of article.
Correspondence to
Dr Pramit Khetrapal;  
 p. khetrapal@ ucl. ac. uk
Protocol
© Author(s) (or their 
employer(s)) 2018. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction Bladder cancer (BC) is a common 
malignancy and one of the most expensive to manage. 
Radical cystectomy (RC) with pelvic lymphadenectomy is 
a gold standard treatment for high-risk BC. Reductions in 
morbidity and mortality from RC may be achieved through 
robot-assisted RC (RARC). Prospective comparisons 
between open RC (ORC) and RARC have been limited by 
sample size, use of extracorporeal reconstruction and 
use of outcomes important for ORC. Conversely, while 
RARC is gaining in popularity, there is little evidence 
to suggest it is superior to ORC. We are undertaking a 
prospective randomised controlled trial (RCT) to compare 
RARC with intracorporeal reconstruction (iRARC) and ORC 
using multimodal outcomes to explore qualitative and 
quantitative recovery after surgery.
Methods and analysis iROC is a multicentre prospective 
RCT in English National Health Service (NHS) cancer 
centres. We will randomise 320 patients undergoing RC 
to either iRARC or ORC. Treatment allocation will occur 
after trial entry and consent. The primary outcome is days 
alive and out of hospital within the irst 90 days from 
surgery. Secondary outcomes will measure functional 
recovery (activity trackers, chair-to-stand tests and health 
related quality of life (HRQOL) questionnaires), morbidity 
(complications and readmissions), cost-effectiveness 
(using EuroQol-5 Domain-5 levels (EQ-5D-5L) and unit 
costs) and surgeon fatigue. Patients will be analysed 
according to intention to treat. The primary outcome will be 
transformed and analysed using regression. All statistical 
assumptions will be investigated. Secondary outcomes 
will be analysed using appropriate regression methods. 
An internal feasibility study of the irst 30 patients will 
evaluate recruitment rates, acceptance of randomised 
treatment choice, compliance outcome collection and to 
revise our sample size.
Ethics and dissemination The study has ethical approval 
(REC reference 16/NE/0418). Findings will be made 
available to patients, clinicians, funders and the NHS 
through peer-reviewed publications, social media and 
patient support groups.
trial registration numbers ISRCTN13680280 and 
NCT03049410.
IntroduCtIon 
Context
Bladder cancer (BC) is a common malig-
nancy and one of the most expensive to 
manage.1 2 Around 25% of BCs present 
with muscle invasion BC (MIBC), and 
these tumours have an ominous prognosis.3 
Radical cystectomy (RC), with pelvic lymph-
adenectomy, represents the gold standard 
treatment for MIBC and plays a key role 
in managing high-risk non-muscle invasive 
cancer and in salvage after radiotherapy.4 RC 
is a major operation associated with frequent 
comorbidity.5 6 Reductions in morbidity and 
mortality from RC have occurred in recent 
years through refined anaesthesia, improved 
surgical techniques, enhanced recovery 
pathways and centralisation of services into 
high volume centres.7–9 Further refinements 
may be achieved through robot-assisted 
surgery.
strengths and limitations of this study
 Ź This is the irst clinical trial to compare qualitative 
recovery after open and robotic radical cystectomy.
 Ź The use of intracorporeal reconstruction and en-
hanced recovery makes this a comparison of the 
optimal robotic approach against the optimal open 
surgery.
 Ź Many surgeons are learning robot-assisted radical 
cystectomy and so a learning curve element may 
impact the experimental arm.
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Current knowledge: robotic and open rC (orC)
For most abdominal surgery, minimally invasive 
approaches are less morbid than open surgery and 
expedite postoperative recovery without altering cancer 
cure.10 Within minimally invasive techniques, robot-as-
sisted surgery offers improved dexterity, precision and 
vision, with less surgeon fatigue than traditional laparos-
copy. However, there is little or conflicting evidence of 
benefit from robot-assisted RC (RARC) over the open 
approach,11–13 and there are uncertainties about oncolog-
ical outcomes with robotic surgery.14 This may reflect the 
complex nature of this procedure (involving surgery to 
both the urinary and gastrointestinal tracts), limitations of 
the current evidence, the typical patient cohort (elderly, 
smoker, pre-existing cardiopulmonary disease) or a true 
lack of difference. Prospective comparisons between 
ORC and RARC have been of limited size and design.15–18 
For example, a three-arm comparison randomised 60 
patients to open, laparoscopic or robotic extracorporeal 
RC.16 Each arm had a single surgeon, and the sample size 
prevented robust comparisons. The largest published 
study to date found no difference in postoperative 
outcomes for 118 patients in two arms.15 This trial was 
criticised as the extracorporeal route mitigated potential 
benefits of RARC,19 and there was an unexplained patient 
preference for ORC (7% randomised to RARC opted for 
ORC vs 0% in other direction). The largest prospective 
study (307 patients) of ORC versus extracorporeal RARC 
is yet to report.17
recovery after surgery
Recovery after laparoscopic and open surgery is mostly 
compared using length of stay (LOS), operating time and 
procedure costs. However, LOS is affected by Enhanced 
Recovery After Surgery (ERAS) pathways, healthcare 
design and social care facilities and misses postdischarge 
readmissions. Readmission is common and can be 
prolonged following RC.8 20 Operating times and proce-
dural costs appear robust, but they can reflect surgeon 
choice and experience, and billing practice rather than 
procedural outcomes.21 Finally, these measures focus 
solely on patient-based rather than surgeon-based metrics.
surgeon fatigue
The impact of surgeon fatigue on patient care, and the 
ability of robot assistance to reduce this, is poorly studied 
and understood.22 23 Validated measures of workload (eg, 
SURG-TLX tool24), mental effort and gaze control can 
assess surgeon fatigue and be used to compare robotic 
and open surgery. Previous work has demonstrated that 
surgeons perform tasks more quickly and accurately with 
fewer errors on a robotic system.25 Self-reported measures 
of workload and mental effort were significantly lower on 
a robotic compared with laparoscopic system. Similarly, an 
objective cardiovascular measure found less mental effort 
was needed on a robotic platform compared with lapa-
roscopy.26 These findings suggest tasks can be performed 
more proficiently, with less workload and mental effort 
using a robot.26 This may allow surgeons greater cogni-
tive resources for dealing with other demands such as 
communication, decision making or periods of increased 
complexity in the operating room. There may also be 
implications for productivity in the operating room as 
surgeons appear capable of delivering a higher number 
of complex procedures per theatre day compared with 
open or laparoscopic surgery.
research need
To determine differences between iRARC and ORC may 
require a multidimensional approach. With regards to 
hospital stay, a parameter such as days alive and out of 
hospital (DAOH) during a predefined perioperative 
period27 (including LOS and readmission) will give a 
more realistic estimate of recovery time. Post operative 
complication rates and quality of life (QoL) measures 
can be more discriminatory between techniques, as they 
directly reflect postoperative return to normal life and 
the smoothness of the perioperative period. There are 
various ways to compare patient experience and QoL. 
These include hospital outcomes, such as LOS and post-
operative complications, and assessment instruments 
such as EQ-5D-5L,28 WHO Disability Assessment Schedule 
2.0 (WHODAS-2)29 and European Organisation for 
Research and Treatment of Cancer (EORTC) Quality 
of Life Questionnaire (QLQ)-Bladder Muscle-invasive 
30 questions (BLM30).30 31 In addition, functional tools, 
such as wearable tracking devices (eg, Fitbit) or activity 
tests can be used to quantitate activity over time. As such, 
we are undertaking a prospective randomised controlled 
trial (RCT) to compare recovery, safety and outcomes 
from ORC and iRARC.
study aims and outcomes
We aim to prospectively randomise eligible patients to 
either iRARC or ORC and measure their recovery in order 
to compare oncological outcomes, safety and cost-effec-
tiveness and determine the role of both approaches in 
patient care. Our primary outcome is:
i. To compare the number of DAOH within 90 days 
from surgery.
Secondary outcomes will assess recovery, complications, 
cost-effectiveness and surgeon fatigue across five domains:
Recovery from surgery
The following tools will measure recovery:
i. Overall functional recovery: self-administered 
WHODAS-2 (12-point) questionnaire at baseline 
(preoperative), 1 month, 3 months, 6 months and 12 
months after surgery.
ii. Cystectomy specific impact on HRQOL: EORTC 
QLQ-BLM30 and Quality of life questionnaire cancer 
30 questions (QLQ-C30) questionnaires at baseline 
(preoperative), 1 month, 3 months, 6 months and 12 
months after surgery.
iii. Quantified activity levels: steps (total and daily aver-
age) taken over consecutive days (measured using a 
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wearable tracking device, eg, Fitbit test) at baseline (7 
days preoperative), 5 days postoperative, 1 month (7 
days), 3 months (7 days), 6 months (7 days) and 12 
months (7 days).
iv. 30 Second chair to stand test: number of times the 
patient can stand from sitting in a 30 s interval. This 
will be counted in the outpatients clinic at baseline 
(preoperative), 1 month, 3 months, 6 months and 12 
months.32 33
v. Qualitative and economic analysis: EQ-5D-5L at base-
line, 1 month, 3 months, 6 months and 12 months.
Perioperative morbidity
To assess perioperative morbidity, the following data will 
be collected:
i. Adverse events recorded using the Clavien-Dindo 
classification.
ii. Readmission to hospital within 90 days of surgery.
iii. Intraoperative and postoperative blood transfusion 
rates.
iv. Length of days in critical care.
v. Rate of radiological or surgical intervention.
vi. Readmission to intensive treament unit (ITU).
vii. 30-Day and 90-day mortality rate.
viii. Conversion from iRARC to open ORC.
ix. Conversion from intracorporeal to extracorporeal 
reconstruction.
Oncological outcomes
To assess the oncological outcomes from surgery, the 
following data will be collected:
i. The number of retrieved lymph nodes in the patho-
logical specimen.
ii. Positive margin rate in the pathological specimen.
iii. Port site recurrence free survival.
iv. Location of recurrence/metastases.
v. Overall and cancer-free survival at 12 and 18 months.
Surgeon fatigue
A substudy will evaluate surgeon fatigue. Specifically, 
immediately following surgery, for 50 IRARC and 50 
ORC cases, the surgeons will be tested using a validated 
psychometric test called SURG-TLX.34 This tool questions 
mental demand, physical demand, temporal demand, 
performance and effort and quantifies response using a 
Likert scale.26
Cost-effectiveness
Cost-effectiveness and quality-adjusted life years (QALYs) 
of iRARC against ORC will be estimated using resources 
used, unit costs and EQ-5D-5L (collected at baseline, 
1 month, 3 months, 6 months and 12 months).
MEthods And dEsIgn
trial design
iROC is a prospective multicentre RCT in patients under-
going RC for BC. Eligible patients will be consented and 
randomised 1:1 to iRARC or ORC after multidisciplinary 
team (MDT) review in National Health Service (NHS) 
cancer centres. It is not possible to blind patients or staff 
to the treatment received. The primary outcome will be 
measured 90 days after RC and secondary outcomes up to 
12 months. Patients will include those receiving neoadju-
vant chemotherapy (typically gemcitabine and cisplatin) 
and those having either an ileal conduit or a neobladder 
reconstruction.
trial population
We aim to recruit 320 patients (figure 1), with an internal 
analysis after the first 30 days. Prior to entry, patients 
must be accurately staged (eg, cross-sectional imaging 
(eg, CT) of the abdomen, pelvis and thorax or bone scan 
if indicated), within 3 months prior to randomisation 
and judged to be eligible for both treatments. Anaes-
thetic evaluation will be used in those with borderline 
fitness. After trial entry, women of childbearing age must 
be proven to be not pregnant (pregnancy test). Eligible 
participants will fulfil all the inclusion criteria and none 
of the exclusion criteria as defined below:
Inclusion criteria
i. Participants must be over 18 years of age.
ii. Histopathological confirmation of BC (Urothelial Cell 
Carcinoma (UCC), Squamous Cell Carcinoma (SCC), 
adenocarcinoma or rare variant).
iii. Carcinoma in situ (CIS) or stage pTa or pT1 or 
≥pT2 or mobile bladder mass on bimanual examina-
tion under anaesthesia.
iv. Node status ≤N1 on imaging criteria or positron emis-
sion tomography  (PET)–ve outside pelvis.
v. Eastern Cooperative Oncology Group (ECOG) grade 
1, 2 or 3.
vi. Able to give informed written consent to participate.
Exclusion criteria
i. Unwilling to undergo cystectomy.
ii. Previous abdominal surgery rendering them unsuit-
able for either iRARC or ORC.
iii. Patients with upper urinary tract disease.
iv. Concomitant disease that would render the patient 
unsuitable for the trial.
v. Pregnant or lactating females.
vi. Previous radiotherapy for BC.
Eligibility waivers are not permitted.
sample size
The primary outcome measure is log(90-DAOH) within 
the first 90 days from surgery. This is expected to be 
approximately normally distributed. For the power calcu-
lation, we estimated the characteristics of this measure 
using information on LOS (given the relatively small 
proportion of deaths) in the 2015 British Association of 
Urological Surgeons (BAUS) national dataset. We aim to 
detect a difference between groups of 0.22 units, assuming 
a conservative SD of 0.7 units. Using a 5% significance 
level and 80% power, it is calculated that 160 subjects per 
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group, 320 in total, are required for the study. Thus, we 
aim to recruit 320 patients.
We note that the original primary outcome was 
log(DAOH). However, a review of blinded internal pilot 
data suggested that this outcome would be left skewed 
and that other sample size assumptions would not hold.
Internal feasibility study
There is a recognition that surgical RCTs can be hard to 
recruit to and that patients may not accept their allocated 
treatment option.35 Furthermore, with respect to iROC, 
little is known about the secondary outcome activity 
measures in the context of post-RC recovery. As such, we 
will undertake an internal feasibility study of the first 30 
patients to look at rates of recruitment, acceptance of 
allocated treatment and collection of outcomes. In addi-
tion, the statistician will use blinded aggregate data to 
check the assumptions used to calculate the sample size. 
If necessary, this will be used to revise our sample size.
Patient and public involvement (PPI)
Patient and public stakeholders were made aware of the 
unmet need for research following the NHS England 
Specialised Services Clinical Commissioning Policy 
(16033/P) statement to withdraw RARC based on 
lack of evidence. Patient feedback on study design was 
obtained through The Urology Foundation’s (Charity no. 
1128683) peer review process, which includes PPI repre-
sentatives, and through Fight Bladder Cancer (Charity 
no. 1157763). Furthermore, PPI representatives are on 
the Trial Steering Committee (TSC) for iROC and will 
have oversight of the management of the research and 
analysis.
On completion of the study, results will be disseminated 
to patients through their urologists. The results will be 
Figure 1 Detailed study schema. CPET, cardiopulmonary exercise testing; iRARC, RARC with intracorporeal reconstruction; 
OPD, outpatients department; ORC, open RC; PIS, patient information sheet; POD, post-operative day; RARC, robot-assisted 
RC; RC, radical cystectomy; SMDT, Surgical Multi-disciplinary team.
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published following peer review, and anonymised data will 
be presented at national and international conferences.
setting
Participants will be recruited from NHS cancer centres 
undertaking both ORC and iRARC. Recruiting centres 
will be invited by the Trial Management Group (TMG) as 
having well-developed RARC programmes with sufficient 
volume to recruit a reasonable number of patients to the 
trial.
Surgeon and unit accreditation
Variations in surgical team performance produce wide 
differences in outcomes from RC.36 Surgeons and 
surgical teams undertaking radical surgery within this 
study require accreditation from the TMG. Surgeons 
undertaking iRARC need to have completed more than 
30 iRARC (as sole surgeons) and have submitted these 
data to the BAUS Oncology database. Surgeons will also 
need to submit an unedited anonymised video of one 
entire procedure to the trial TMG for review. At the start 
of recruitment, the TMG will organise surgeon training 
days to discuss the surgical aspects of iRARC. Accredited 
surgeons will have undertaken more than 10 RCs per year 
for the last 2 years as primary surgeon, have a median 
LOS under 14 days and will have 90-day post-RC mortality 
rate of less than 5%. Individual surgeon data will act as 
surrogate measures for the entire surgical team.
Radical cystectomy
RC will be performed as is standard of care throughout 
the NHS. In females, this includes anterior pelvic exenter-
ation (with the uterus, fallopian tubes and a component 
of the anterior vaginal wall). The urethra will be excised 
in females choosing an ileal conduit. Oophorectomy is 
individualised for each patient, as per local practice. In 
males, RC includes the prostate and seminal vesicles. 
Nerve sparing to the prostatic neurovascular bundles 
should be attempted as per typical practice. Exceptions 
to this surgical plan are acceptable with prior approval 
from TMG. Pelvic lymphadenectomy should be included 
in all cases, unless contraindicated clinically. The lymph-
adenectomy template should include the external iliac, 
obturator and internal iliac nodes, with a proximal exten-
sion to the level of the ureteric crossing of the common 
iliac vessels. A more extended lymphadenectomy is 
acceptable. Excised lymphatic tissue should be submitted 
for histological analysis. Urinary tract reconstruction 
within this trial is limited to either: (1) ileal conduit or (2) 
orthotopic neobladder (by whichever design is practised 
by that unit (eg, Tan et al37)).
Intervention A: iRARC
Intracorporeal robot assisted radical cystoprostatectomy 
or anterior exenteration should be conducted as per local 
practice using an Intuitive da Vinci system. The proce-
dure should include intracorporeal reconstruction using 
small bowel. Surgeon discretion is allowed for the place-
ment of a pelvic drain, nasogastric tubes, the use of local 
anaesthesia and port site closure. All specimens should be 
removed using impermeable collections bags or surgical 
gloves. Measures to avoid spillage of urine or fluid from 
the specimens must be taken.
Intervention B: ORC
ORC should be performed using a midline incision as per 
local protocols. The procedure should include urinary 
reconstruction using small bowel. Surgeon discretion is 
allowed for the placement of a pelvic drain, nasogastric 
tubes, the use of local anaesthesia and wound closure. 
Regional anaesthesia using rectus sheath blocks or an 
epidural is recommended.
recruitment
iROC will recruit patients attending NHS cancer centres. 
All patients who have a diagnosis of BC in whom the 
specialist MDT have recommended RC as a treatment 
option can be approached.
Consent
Written informed consent will be obtained from each 
patient prior to study entry and performing baseline trial 
assessments. A patient information sheet and informed 
consent form are provided to facilitate this process. The 
investigator, or their designee, must ensure adequate 
explanations of the study, that participation is volun-
tary, and they can withdraw at any time. In consenting 
to the study, participants are consenting to provide study 
follow-up and data collection. Consent to provide liquid 
biopsy (blood, urine) as well as permission to obtain 
paraffin blocks will be requested. Patient who do not wish 
to consent for these translational samples remain eligible 
for the randomised trial. A patient may withdraw from 
the study at any time without prejudice to his or her subse-
quent treatment.
randomisation
Patients will be randomised, using an online system 
(https://www. sealedenvelope. com/ trials/) on a 1:1 basis 
to either iRARC or ORC. A computer-generated adap-
tive minimisation algorithm that incorporates a random 
element will be used to ensure the treatment groups are 
balanced (stratified) for:
 Ź Centre.
 Ź Type of urinary diversion (continent diversion/
neobladder or ileal conduit).
Treatment allocation will occur after trial entry and 
consent.
Data collection
Trial assessments will be conducted at various time inter-
vals (defined around the date of surgery). Schedule of 
events is summarised in table 1. Time points:
i.  Baseline/preoperative: at the time of consent and 
trial entry.
ii. Perioperative: operative details collected immediate-
ly after surgery.
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iii. In-hospital postoperative: recovery from surgery, 
complications and secondary interventions after sur-
gery, activity/mobility at 5 days after RC.
iv. Hospital discharge: time (days) to leaving hospital for 
home.
v. Within 90 days of surgery: readmission to the hospi-
tal, self-completed questionnaires.
vi. Outpatient follow-up: at 5 weeks, 3 months, 6 months 
and 12 months from the date of surgery question-
naires, fitness tracking data and blood tests.
The time point of interest for measurement of the 
primary endpoint will be 90 days. Patients will continue to 
receive routine clinical follow-up (at 4–6 weeks, 3 months, 
6 months, 12 months). Subject to additional funding, we 
also propose a future extension to collect overall and 
cancer-free survival data at 18 months.
the secondary endpoint measures include
i. EQ-5D-5L (baseline, 5 weeks, 3 months, 6 months 
and 12 months): a self-completion tool for patients 
that is applicable to a wide range of health condi-
tions and treatments. Measured domains include 
mobility, self-care, usual activities, pain and anxiety 
or depression.28
ii. WHODAS 2.0 (baseline, 5 weeks, 3 months, 6 months 
and 12 months): a generic assessment instrument 
for health and disability used across all diseases, in-
cluding mental, neurological and addictive disorders 
directly linked at the level of the concepts to the 
International Classification of Functioning, Disability 
and Health. WHODAS 2.0 covers six domains of 
functioning, including cognition, mobility, self-care, 
getting along, life activities and participation.29
iii. EORTC QLQ-BLM30 Version 1 (baseline, 5 weeks, 3 
months, 6 months and 12 months): a 30-item ques-
tionnaire for patients with BC (T2, T3, T4a and T4b). 
This module is designed to be used in conjunction 
with QLQ-C30 and includes an assessment of uri-
nary symptoms, bowel symptoms, sexual functioning, 
Table 1 Timing of events and outcome collection within iROC
Baseline RC Postoperative Visit 2 Visit 3 Visit 4 Visit 5
Time Preoperative Day 0 POD 4–7 5 weeks±2 
weeks
12 
weeks±2 
weeks
24 
weeks±4 
weeks
1 year±4 
weeks
Informed consent and randomisation x
Demographic data, medical history and 
so on
x
Physical examination and vital signs x
Fitness for surgery assessment x
12-lead ECG and CPET testing* x
Haematology and biochemistry x x x x X
Pregnancy test† x
Translational and research bloods‡ x x x x X
Urinalysis x
Urine collection for research‡ x
Chest, abdomen and pelvis imaging§ x x X
Clavien-Dindo assessment x x x
Adverse events x x x x x X
Tumour sample x
Parafin embedded tissue x
Survival and treatment data x x x x X
EQ-5D-5L x x x x X
WHODAS 2.0 x x x x X
EORTC QLQ-BLM30 x x x x X
30 s chair to stand test x x x x x X
Quantiied activity levels (steps tracker) x x x x x X
*Cardiopulmonary exercise testing only in participating centres that routinely perform this test.
†Can be urine or blood-based pregnancy test, depending on site’s standard of care.
‡Home collection kit to be given.
§Imaging schedule is not mandated by the trial. However, if imaging studies have been conducted, these results are collected.
POD, postoperative day; RC, radical cystectomy.
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urostomy problems, problems associated with the use 
of a catheter and body image.30 31
iv. Quantified activity levels (baseline, 5 days , 5 weeks , 3 
months , 6 months and 12 months). Fitness tracking 
devices will record steps taken for seven consecutive 
days at predetermined time points.38 The WHO 30 s 
sit to stand test will also be administered at these time 
points.32
v. Operative: intraoperative surgical details will be re-
corded (intraoperative case report form (CRF)). 
Missing data extracts will be obtained from the BAUS 
complex cancer database. The following operative 
measures will be recorded:
  Duration of surgery (total and individually for 
cystectomy, lymph node dissection (LND), uri-
nary diversion times).
  Grade of operator.
  Training op (yes/no).
  Conversion rate.
  Operative blood loss.
  Operative blood transfusion rate.
  Visceral injury.
  Vascular injury.
  Death.
  Return to theatre.
vi. Postoperative: an inpatient postoperative assessment 
CRF will be used to record progress. Clavien-Dindo 
classification of surgical complications will be used to 
assess for any surgical complications as per normal 
hospital practice. These scores will be recorded at 30 
and 90 days postcystectomy.39 40
vii. Oncological outcomes (3 months, 6 months and 12 
months): the curative outcomes from the RC will be 
examined at 3, 6 and 12 months to determine local 
and distant recurrence, metastases, need for palliative 
treatment and survival (overall and cancer specific). 
CT scans will be undertaken at 12 months, according 
to usual practice, and if clinically indicated.
viii. Cost-effectiveness: the study will follow good prac-
tice guidelines for economic evaluations undertak-
en alongside controlled trials. Differences between 
patients in the two arms will be calculated and 
cost-effectiveness will be compared against funding 
thresholds used by the National Institute for Health 
and Care Excellence (NICE). Costs will be calculat-
ed from resources used and unit cost. Key resources 
are robotic equipment, theatre consumables, theatre 
time and staffing, length of hospital stay, complica-
tions, readmissions and ambulatory care (eg, out-
patients, generap practitioner (GP) visits and nurse 
visits), and these will be prospectively collected within 
each hospital and in an ambulatory setting. Unit costs 
(collection prices) will be derived from NHS business 
managers and NHS Tariffs for each centre contrib-
uting 20 or more cases into iROC. We will calculate 
total costs and QALYs for each patient and estimate 
the incremental costs and QALYs using a seemingly 
unrelated regression model with baseline covariates 
including age and baseline EQ-5D-5L score and miss-
ing data imputed using multiple imputation (EQ-5D-
5L collected at baseline, 5 weeks, 3 months, 6 months 
and 12 months)). QALYs will be estimated using EQ-
5D-5L values using the official EuroQoL Group tariff 
and using linear interpolation between time points. 
Following this analysis, bootstrapping will be used to 
generate the cost-effectiveness plane and associated 
cost-effectiveness acceptability curves. Deterministic 
sensitivity analyses will be undertaken using the EQ-
5D-3L tariff using a crosswalk algorithm. Undertaking 
a sensitivity analysis with the 3 L tariff is required as 
the 5 L tariff has yet to be adopted by NICE or accept-
ed more generally by economists/researchers.
statistical analyses
A detailed statistical analysis plan will be written before any 
analysis is undertaken. All analyses and data summaries 
will be conducted using the groups to which the patients 
were randomised and patient will be included regardless 
of whether they received the allocated treatment (inten-
tion to treat (ITT)). Statistical tests and CIs will be two 
sided, and estimates of treatment effects will be presented 
with 95% CIs and significance will be considered at the 
5% level. No formal interim analyses are planned.
The flow of study participants will be displayed in a 
Consolidated Standards of Reporting Trials diagram, 
and the baseline characteristics of the patients will be 
summarised by trial arm using appropriate descriptive 
statistics. The primary analysis will be a comparison of 
the transformed primary outcome DAOH using regres-
sion to adjust for the minimisation factors. The secondary 
outcomes will also be analysed using appropriate regres-
sion methods. The use of mixed models will be consid-
ered for those secondary outcomes measured at several 
time-points. All statistical assumptions will be investigated. 
Potential bias due to missing data will be investigated by 
comparing descriptively the baseline characteristics of the 
trial participants with complete outcome measurements 
to those who have missing outcome measurements. The 
use of regression (to adjust for variables related to missing-
ness) and multiple imputation methods (chained equa-
tions) will be considered as sensitivity analyses. Patients 
will be offered the option of telephonic follow-up if they 
are unable to attend clinic appointments for follow-up. 
Additionally, patients wishing to withdraw from the trial 
will be counselled regarding end of active participation, 
as this would allow the trial team to collect outcome data 
for an ITT analysis. For patients who consent into the trial 
but ultimately do not undergo RC, only survival data will 
be collected.
safety
The number of adverse events and related unexpected 
serious adverse events (SAEs) will be summarised 
descriptively by arm, by grade and body system. The 
proportion of participants experiencing each toxicity 
will be summarised by maximum NCI CTCAE grade41 
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experienced, overall and by arm. RC is a major operation 
that has a number of recognised complications and a low 
risk of death (less that 1 in 100). Expected adverse events 
will be reported as per previous reports5 6:
 Ź Gastrointestinal (29%): ileus, small bowel obstruc-
tion (SBO), constipation, clostridium difficile colitis, 
gastrointestinal bleeding, emesis, anastomotic bowel 
leak and diarrhoea.
 Ź Infectious (25%): fever of unknown origin (FUO), 
abscess, urinary tract infection (UTI), sepsis, 
urosepsis, pyelonephritis, diverticulitis, gastroenteritis 
and cholecystitis).
 Ź Wound (15%): wound seroma, wound infection, 
wound dehiscence and facial dehiscence/evisceration.
 Ź Genitourinary (11%): renal failure, ureteral obstruc-
tion, urinary leak, urinary fistula, urinary retention, 
parastomal hernia, stomal ischaemia and haematuria.
 Ź Cardia (11%): arrhythmia, myocardial infarction, 
hypertension, congestive heart failure, angina and 
hypotension.
 Ź Pulmonary (9%): atelectasis, pneumonia, respiratory 
distress, pneumothorax, and pleural effusion.
 Ź Bleeding (9%): anaemia requiring transfusion, post-
operative bleed other than GI and wound haematoma.
 Ź Thromboembolic (8%): deep vein thrombosis, 
pulmonary embolism and superficial phlebitis.
 Ź Neurological (5%): peripheral neuropathy, cere-
brovascular accident transient (CVA)/transient 
ischaemic attack (TIA), delirium/agitation, vertigo, 
loss of consciousness and seizure.
Operative/postoperative RC complications will be 
graded using the Clavien-Dindo classification.39 40 All 
SAEs will be recorded in the medical records, the CRF, 
the sponsor’s adverse event (AE) log and an SAE form. 
The principal investigator (PI) or designated individual 
will complete an SAE form, and the form will be faxed 
to surgical and interventional trials unit (SITU) within 
five working days of becoming aware of the event. The 
chief or PI will respond to any SAE queries raised by the 
sponsor as soon as possible. Where the event is unex-
pected and thought to be related to the procedure, this 
must be reported by the investigator to SITU, who will 
then inform the Health Research Authority within 15 
days.
data monitoring
This study will use an electronic case report form 
(eCRF), and trial data will be entered into an approved, 
protected database (https://www. elsevier. com/ solu-
tions/ macro). Access to the eCRF system will only be 
provided to staff with relevant authority. Participants 
will be given a unique subject number and subject 
identifier. Data will be entered under this identifica-
tion number onto the central database stored on the 
servers. The database will be password protected and 
only accessible to members of the iROC study team 
and external regulators if requested. The servers are 
protected by firewalls and are patched and maintained 
according to best practice. The physical location of the 
servers is protected by CCTV and security door access. 
The database software provides a number of features 
to help maintain data quality, including: maintaining 
an audit trail, allowing custom validations on all data, 
allowing users to raise data query requests and search 
facilities to identify validation failure/missing data. 
After completion of the study, the database will be 
retained on the servers of University College London 
for ongoing analysis of secondary outcomes. The identi-
fication, screening and enrolment logs, linking partici-
pant identifiable data to the pseudoanonymised subject 
numbers will either be held in written form in a locked 
filing cabinet or electronically in password-protected 
form on hospital computers. After completion of the 
study, the identification, screening and enrolment logs 
will be stored securely by the sites for 10 years unless 
otherwise advised by sponsor.
trial funding, organisation and administration
The trial was developed by the iROC TMG and funded 
by The Urological Foundation and Champniss Chari-
table Trust. Intuitive Surgical has contributed dispos-
able surgical equipment to the iRARC arm but has had 
no role in trial design and will have no role in trial 
implementation, analysis, interpretation or writing any 
reports. The trial is sponsored by University College 
London and registered with ISRCTN (13680280) and 
ClinicalTrials. gov (NCT03049410) on 10 February 2017. 
Members of the trial team are Good Clinical Practice 
(or equivalent) trained. A Data Monitoring Committee 
(DMC) will monitor patient safety and the rate of 
recruitment of subjects in the study. They will meet at 
least once a year while the trial is ongoing for routine 
review of safety data and trial progression. They have 
the power to call additional meetings and review data 
at any point in the trial should they wish to do so. The 
DMC may report their findings to the TSC. The TSC is 
an independent committee consisting of relevant, expe-
rienced clinicians and researchers. The TSC will ensure 
the study is conforming to governance requirements as 
set out by the trial sponsor. The TSC will meet at least 
once a year. The sponsor may also arrange an indepen-
dent trial monitor to review the study data.
dIsCussIon
Since its introduction, robot-assisted surgery has rapidly 
gained popularity despite a lack of evidence of its supe-
riority over other approaches. For example, in England, 
most NHS Radical Prostatectomies are performed using 
robot assistance (https://www. baus. org. uk/ patients/ 
surgical_ outcomes/ radical_ prostatectomy/ default. 
aspx). With regards to RC, in 2016, 40% of the 1279 RCs 
submitted to the BAUS Complex Operation database 
(which covers 91% of cases in England and Wales using 
healthcare quality improvement partnership (HQIP) 
data) involved robotic surgery. This compares to 31% 
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in 2015 and 14.5% in 2014. While single surgeon 
series demonstrate favourable outcomes from robotic 
surgery,42 prospective clinical trials and population 
surveys have found minimal benefit that may not justify 
the additional cost.43–45 This has left many healthcare 
funders in a difficult position. For example, a NHS 
England Specialised Services Clinical Commissioning 
Policy (16033/P) stated it would no longer routinely 
commission RARC, despite the trend to increase RARC 
within the NHS.
The popularity of robotic surgery among patients, 
surgeons and hospitals suggests that observed marginal 
benefits may be more important than the data suggest 
or that other benefits have not been demonstrated. 
With this in mind, we developed iROC to test a fully 
intracorporeal approach against ORC to focus on the 
quality of patient recovery and to test surgeon fatigue. 
RC may be an ideal procedure for robotic assistance 
given its surgical complexity, typical comorbid patient 
cohort and potential for economic savings from 
reduced morbidity and faster hospital discharge. RC 
is a two-stage procedure involving: (1) removal of the 
bladder and (2) urinary tract reconstruction. Following 
robot-assisted bladder removal, many surgeons under-
take reconstruction through an open incision (so called 
extracorporeal). This is less technically challenging 
than robotic intracorporeal reconstruction but leads to 
increased cost (open and robotic instruments needed) 
and leaves the patient with both robotic and open inci-
sions. To date, prospective comparisons of open and 
robotic RC have been limited by the use of an extracor-
poreal reconstruction. To overcome this limitation, we 
have mandated intracorporeal reconstruction in iROC.
Current data and RCTs have also used primary 
outcomes that matter most in open surgery (eg, trans-
fusion rate, LOS and pathology). To overcome this, 
we have additionally focused on qualitative recovery. 
However, little is known of these qualitative outcomes 
after RC (either open or robotic) and patient compli-
ance with the collection of these measures. We have 
planned an internal pilot phase (30 patients) to review 
secondary outcome collection and may adapt sample 
size or outcome collection following this.
EthICs And dIssEMInAtIon
The results of the study will be published in peer-re-
viewed publications and will be presented at relevant 
national and international conferences. We will work 
with our patient panel to develop lay reports to dissemi-
nate research findings to patient groups and the clinical 
teams at participating sites.
Availability of data
SITU, the CTU will control the final trial dataset, and 
any requests for access will be reviewed by the TMG and 
TSC and subject to existing contractual arrangements 
with the funders. The protocol, sample case report 
forms and participant information are available on a 
case by case basis as agreed by the TMG, on request to 
the corresponding author.
trIAl stAtus
The trial opened to recruitment in March 2017 using 
protocol version 1.0 (dated November 2016) and is due 
to close in February 2020 or after accrual and the last 
patient visit is completed. The protocol was amended 
to version 2.0 in May 2017 to account for additional 
inclusion and exclusion criteria, and updated surgeon 
accreditation criteria. Both amendments were reviewed 
and approved by the sponsor and the National Research 
Ethics Service Committee. Protocol amendments are 
disseminated to relevant parties by SITU.
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